7179 related articles for article (PubMed ID: 20432186)
1. American Academy of Dermatology-68th annual meeting. 5-9 March 2010, Miami Beach, FL, USA.
Whang T; Goldenberg G
IDrugs; 2010 May; 13(5):311-3. PubMed ID: 20432186
[TBL] [Abstract][Full Text] [Related]
2. Report from the 67th annual meeting of the American Academy of Dermatology.
Alexandroff AB; Graham-Brown RA
Br J Dermatol; 2010 Jan; 162(1):12-21. PubMed ID: 19659467
[TBL] [Abstract][Full Text] [Related]
3. BRAF inhibitors: research accelerates in wake of positive findings.
Brower V
J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
[No Abstract] [Full Text] [Related]
4. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
5. American Academy of Dermatology - 2010 summer meeting.
Carlos M; Goldenberg G
IDrugs; 2010 Oct; 13(10):683-5. PubMed ID: 20878586
[TBL] [Abstract][Full Text] [Related]
6. 67th annual meeting of the American Academy of Dermatology: San Francisco, California, USA, 6-10 March 2009.
Fraser K
Am J Clin Dermatol; 2009; 10(3):205-10. PubMed ID: 19354337
[No Abstract] [Full Text] [Related]
7. A report from the 68th annual meeting of the American Academy of Dermatology (March 5-9, 2010 - Miami, Florida, USA).
Rabasseda X
Drugs Today (Barc); 2010 Jun; 46(6):437-48. PubMed ID: 20571613
[TBL] [Abstract][Full Text] [Related]
8. Dermatology update: The dawn of targeted treatment.
Fernandez A
Cleve Clin J Med; 2015 May; 82(5):309-20. PubMed ID: 25973879
[TBL] [Abstract][Full Text] [Related]
9. Targeting metastatic melanoma.
Flaherty KT
Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
[TBL] [Abstract][Full Text] [Related]
10. [Genetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum].
Doma V; Gulya E
Orv Hetil; 2015 Apr; 156(15):583-91. PubMed ID: 25845317
[TBL] [Abstract][Full Text] [Related]
11. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
12. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of melanoma.
Pickert A
Cutis; 2012 Mar; 89(3):E1-4. PubMed ID: 23961517
[No Abstract] [Full Text] [Related]
14. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
15. [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].
Haase O; Angün O; Grätz V; Lüttmann N; Neumann A; Zillikens D; Terheyden P
Hautarzt; 2016 Aug; 67(8):648-52. PubMed ID: 27146499
[TBL] [Abstract][Full Text] [Related]
16. Molecularly targeted therapies for melanoma.
Liu LS; Colegio OR
Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
[TBL] [Abstract][Full Text] [Related]
17. 68th annual meeting of the American Academy of Dermatology: Miami Beach, Florida, USA, 5-9 March 2010.
Fraser K
Am J Clin Dermatol; 2010; 11(3):223-4. PubMed ID: 20369904
[No Abstract] [Full Text] [Related]
18. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
[TBL] [Abstract][Full Text] [Related]
19. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
